Harnessing transcription factor-driven ROS for synergistic multimodal lung cancer treatment
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.08.035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Ye Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'…. Hauptthemen laut MEDLINE: Lung Neoplasms, Reactive Oxygen Species, Prodrugs, Antineoplastic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Xi’an Jiaotong University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Multimodal treatment of cancer is an unstoppable revolution in clinical application. However, designing a platform that integrates therapeutic modalities with different pharmacokinetic characteristics remains a great challenge. Herein, we designed a universal lipid nanoplatform equipping a ROS-cleavable docetaxel prodrug (DTX-L-DTX) and an NF-E2-related factor 2 (NRF2) inhibitor (clobetasol propionate, CP). This simply fabricated nanomedicine enables superior synergistic molecularly targeted/chemo/radio therapy for lung cancer cascade by a transcription factor-driven ROS self-sustainable motion. Chemotherapy is launched via ROS-triggered DTX release. Subsequently, CP inhibits the expression of NRF2 target genes, resulting in efficient targeted therapy, meanwhile inducing sustained ROS generation which in turn facilitates chemotherapy by overcoming ROS consumption during the DTX release process. Finally, the introduction of radiotherapy further amplifies ROS, offering continuous mutual feedback to amplify the ultimate treatment performance. This strategy is conceptually and operationally simple, providing solutions to challenges in clinical cancer treatment and beyond.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an 710061, PR China; Department of Endocrinology, The First Affiliated…
- Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an 710061, PR China; National Engineering Research Center for Miniaturized Detection Systems, College of L…
- Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an 710049, PR China. Electronic address: zhujian@mail.xjtu.edu.cn.
Förderung
- Xi’an Jiaotong University
- National Natural Science Foundation of China
Zitieren
APA
Zhou, Y., Wang, S., Guo, J., Li, C., Sui, M., Zeng, Z., Dang, H., Gu, Q., Zhu, J., Cheng, Y., & Hou, P. (2024). Harnessing transcription factor-driven ROS for synergistic multimodal lung cancer treatment. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.08.035
Vancouver
Zhou Y, Wang S, Guo J, Li C, Sui M, Zeng Z, et al. Harnessing transcription factor-driven ROS for synergistic multimodal lung cancer treatment. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.08.035
BibTeX
@article{Zhou2024,
author = {Zhou, Ye and Wang, Simeng and Guo, Jiahua and Li, Chenghao and Sui, Mengjun and Zeng, Zekun and Dang, Hui and Gu, Qingqing and Zhu, Jian and Cheng, Yangyang and Hou, Peng},
title = {Harnessing transcription factor-driven ROS for synergistic multimodal lung cancer treatment},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.08.035}
}
EUVIMED